As of 2026-03-15, the Intrinsic Value of Cardiol Therapeutics Inc (CRDL.TO) is -1.56 CAD. This CRDL.TO valuation is based on the model Peter Lynch Fair Value. With the current market price of 1.43 CAD, the upside of Cardiol Therapeutics Inc is -208.90%.
Based on its market price of 1.43 CAD and our intrinsic valuation, Cardiol Therapeutics Inc (CRDL.TO) is overvalued by 208.90%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -1.56 - -1.56 | -1.56 | -208.90% |
| P/E | (2.59) - (3.71) | (3.24) | -326.5% |
| DDM - Stable | (2.62) - (9.86) | (6.24) | -536.7% |
| DDM - Multi | (1.27) - (3.77) | (1.91) | -233.3% |
| Market Cap (mil) | 159.70 |
| Beta | 1.75 |
| Outstanding shares (mil) | 111.68 |
| Enterprise Value (mil) | 148.21 |
| Market risk premium | 5.10% |
| Cost of Equity | 9.57% |
| Cost of Debt | 5.00% |
| WACC | 9.57% |